Sanofi and San Diego-based Isis Pharmaceuticals Inc. (Nasdaq: ISIS) won the support of U.S. regulatory advisers for its drug that treats a hyper form of high cholesterol in people with a rare genetic disease.
The companies provided sufficient data on the safety and efficacy of the injection Kynamro, advisers to the Food and Drug Administration voted Thursday at a meeting in Silver Spring, Md. The recommendation, which now has to be vetted by the FDA, comes a day after Aegerion Pharmaceuticals Inc. won the panel’s backing for a similar drug in pill form.
1896 Rutherford Road
Carlsbad, CA 92008